Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tempest Therapeutics, Inc. - Common Stock
(NQ:
TPST
)
0.7116
-0.0084 (-1.17%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tempest Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 25, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
November 12, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 30, 2024
Via
Benzinga
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
October 30, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 16, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
October 10, 2024
Via
Benzinga
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
October 10, 2024
Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in patients...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 10, 2024
Via
Benzinga
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
October 10, 2024
The company is preparing for the Phase 3 study start in the first quarter of 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Extends Limited Duration Stockholder Rights Plan
October 10, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 20, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
September 18, 2024
Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal study
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 23, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
August 21, 2024
Expansion of leadership team to strengthen global clinical expertise
From
Tempest Therapeutics
Via
GlobeNewswire
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
August 15, 2024
Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin...
Via
Benzinga
Exposures
Product Safety
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
August 15, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
TPST Stock Earnings: Tempest Therapeutics Misses EPS for Q2 2024
August 09, 2024
TPST stock results show that Tempest Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
$55M Bet On Archer Aviation? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
July 05, 2024
Via
Benzinga
Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
June 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 20, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
June 20, 2024
Via
Benzinga
Gold Rises 1%; Accenture Shares Surge After Q3 Results
June 20, 2024
Via
Benzinga
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
June 20, 2024
Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients...
Via
Benzinga
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
June 20, 2024
NLS Pharmaceutics stock is down on Thursday as shares of NLSP come off of a recent rally that was fueled by heavy trading on Tuesday.
Via
InvestorPlace
Why Is Avrobio (AVRO) Stock Moving Today?
June 20, 2024
Avrobio stock is in the news Thursday as the company prepares for a merger and reverse stock split of AVRO after markets close today.
Via
InvestorPlace
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
June 20, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.